Document:

Share Transfer Agreement, dated as of July 18, 2006

 Exhibit 10.5 
 English translation of the executed copy 
  

 Agreement Regarding Transfer of Equity Interest In 
 Shenyang Sunshine
Pharmaceutical Co., Ltd. 
  

 By and Between 
 Starry Investment Limited 
 and 
 Collected Mind Limited 

 Equity Interest Transfer Agreement 
 This Agreement is entered into on 18 July 2006 in Shenyang by and between: 
 Transferor: Starry Investment Limited 
 Legal Address: P. O. Box 217, Apia, Samos 
 Legal Representative: Liu Xiaomeng 
 And 
 Transferee: Collected Mind Limited 
 Legal Address: P.O. Box 957, Offshore Incorporations Centre, Road Town, Tortola,

 British Virgin Islands 
 Authorized Representative: Lou Dan

 WHEREAS: 
  

	1.	The Transferor is a company is a company duly incorporated and validly existing pursuant to the laws of British Virgin Islands, and legally holds a 3.33% equity interest
(hereinafter referred to as the “Subject Equity Interest”) in Shenyang Sunshine Pharmaceutical Co., Ltd. (hereinafter referred to as “Sunshine Pharmaceutical”); 

  

	2.	The Transferee is a company duly incorporated and validly existing pursuant to the laws of British Virgin Islands. It is validly qualified to be transferred of the equity interest
in Sunshine Pharmaceutical pursuant to relevant laws; 

  

	3.	Sunshine Pharmaceutical is a Sino-foreign equity joint venture incorporated in Shenyang and validly existing pursuant to the laws of China. Its principal business is to research,
develop, manufacture and sell biologically-engineered products and biochemical pharmaceuticals. It has a registered capital of Renminbi 62,974,046 which has already been fully contributed. Its existing shareholders are Chinese investors Shenyang
Keweier Hi-Tech Co., Ltd. (hereinafter referred to as “Keweier”), China Traffic Supplies Northeast Co., Ltd. (hereinafter referred to as “Traffic Supplies”), Zhang Lisha as well as foreign investors Montgomery Biomedicine Lab
Inc. of the USA (hereinafter referred to as “Montgomery”), Lans Holdings Ltd. (hereinafter referred to as “Lans Holdings”) and the Transferor, among which Keweier holds a 50.88% equity interest in Sunshine Pharmaceutical; Traffic
Supplies, 6.67%; Zhang Lisha, 8.23%; Montgomery, 17.89%; Lans Holdings, 13.01% and the Transferor, 3.33%. 

  

 1 

	4.	The Transferor desires to sell, and the Transferee desires to purchase, the Subject Equity Interest under the terms and conditions hereof. 

 NOW THEREFORE, the Transferor and the Transferee agree as follows: 
 Article
1: Equity Interest Transfer 
  

	1.	The Transferor hereby agrees to transfer the Subject Equity Interest to the Transferee pursuant to the stipulations hereof. 

  

	2.	The Transferee shall be transferred of the Subject Equity Interest pursuant to the stipulations hereof. 

  

	3.	As of the later of the date on which this Agreement becomes effective and the date on which Sunshine Pharmaceutical completes its registration with relevant government
administration offices industry and commerce for the transfer of the Subject Equity Interest, the Transferee shall immediately become the legal owner of the Subject Equity Interest and be entitled to and assume all the rights and obligations in
relation to the Subject Equity Interest. The Transferor shall no longer be entitled to any rights in relation to the Subject Equity Interest or assume any obligations or liabilities in relation to the Subject Equity Interest, unless otherwise
provided herein. The Transferor shall be obliged to assist the Transferee and Sunshine Pharmaceutical in completing all necessary legal procedures in relation to the transfer of the Subject Equity Interest. 

 Article 2: Purchase Price and Payment 
  

	1.	As agreed by the Transferor and the Transferee upon negotiations, the consideration payable by the Transferee for the Subject Equity Interest shall be US$1;

  

	2.	It is agreed that the Transferee shall pay the purchase price within ten days from the date on which the Transferee is registered as a shareholder of Sunshine Pharmaceutical with
the industrial and commercial registration; 

  

 2 

	3.	Taxes payable in connection with this equity interest transfer shall be paid by both parties as required by relevant laws and regulations. 

 Article 3: Binding Effect 
 This Agreement shall be binding upon the
Parties at the time this Agreement is signed by the authorized representatives of both parties and approved by the competent foreign trade and economic cooperation authority. 
 Article 4: Representations and Warranties of Transferor 
 The Transferor hereby represents and warrants to the
Transferee that: 
  

	1.	The Transferor is a limited company duly established and validly existing pursuant to the laws of British Virgin Islands, and has the corporate power and authority to execute and
perform this Agreement; and this Agreement once executed is legal, valid and binding upon the Transferor. 

  

	2.	The Transferor is the owner of, and has legal and equitable title to the Subject Equity Interest, free and clear of any pledge or any other security interest or any claims by any
third party. The Transferor has the right to execute this Agreement and dispose of the entire Subject Equity Interest or any parts thereof. Such equity interest or any interest in relation thereto is not subject to any preferential right or other
similar rights. Upon completion of the equity interest transfer contemplated hereunder, the Transferee will be entitled to all the rights entitled to an owner of the Subject Equity Interest pursuant to laws, and may transfer or dispose of such
equity interest pursuant to laws, and such equity interest is free from any liens, charges claims, encumbrances, rights of others and restrictions on transfer under the incorporation documents of Sunshine Pharmaceutical or stipulations of the laws
of China. 

  

	3.	The execution, delivery and performance of this Agreement by the Transferor is neither in breach of any laws, administrative regulations, articles of association or other
organizational documents of the Transferor , nor in breach of any contracts, rules and regulations, court judgment or arbitration award which are binding upon the Transferor or its property. 

  

 3 

	4.	Sunshine Pharmaceutical has obtained all approvals, consents, authorizations and licenses necessary for its establishment and business operation. All such approvals, consents,
authorizations and licenses are valid and binding. To the knowledge of the Transferor, no event has ever occurred in connection with its business operation that affects the interest of the Transferee or is in breach of the laws and regulations of
China. 

  

	5.	No such fact that regarding Sunshine Pharmaceutical and that might change the original intent for the execution of this Agreement or any clauses hereof has not yet been disclosed.

  

	6.	Such representations, warranties and undertakings shall still remain in force and effect upon the completion of the transfer of the Subject Equity Interest to the Transferee.

 Article 5: Representations and Warranties of Transferee 
 The Transferee hereby represents and warrants to the Transferor that: 
  

	1.	The Transferee is a limited company duly established and validly existing pursuant to the laws of British Virgin Islands, and possesses all the rights, authorities and capabilities
necessary for entering into and performing all the obligations and liabilities hereunder; and once executed the Agreement is legally and validly binding upon the Transferee. 

  

	2.	The execution, delivery and performance of this Agreement by the Transferee is neither in breach of any laws, administrative regulations, articles of association or other
organizational documents of the Transferee nor in breach of any contracts, rules and regulations, court judgment or arbitration award, which are binding upon the Transferee or its property. 

  

	3.	Such representations, warranties and undertakings shall still remain in force and effect after completion of the transfer of the Subject Equity. 

 Article 6: Confidentiality 
 Unless required by the relevant laws and
regulations of China or relevant competent government departments, none of the parties may, prior to completion of the transaction contemplated herein, disclose any particular of this Agreement to any third party that is not involved in such
transaction without the consent of the other party. 
  

 4 

 Article 7: Matters not Covered by this Agreement 
 The Transferor and the Transferee hereby agree that upon signing of this Agreement, they may further negotiate any matters that is not covered hereof and may reach a supplemental agreement thereon. Such supplemental
agreement shall constitute an inseparable integral part of this Agreement. 
 Article 8: Liability for Breach of Contract 
 Either party is in breach of contract if it violates any of its representations, warranties or undertakings herein or any clauses hereof. The default party shall
indemnify the non-default party in whole and in full. 
 Article 9: Dispute Resolution 
 The parties to the Agreement shall resolve any disputes arising from the performance of this Agreement and in connection therewith through friendly negotiations, failing which either party shall have the right to
institute legal proceedings before a Chinese court with jurisdiction. 
 Article 10: Governing Law 
 This Agreement is entered into under, and shall be governed, construed and controlled by the laws of China. 
 Article 11: Rights under the Agreement 
 None of the parties may transfer its rights entitled hereunder without the
written consent of the other party. This Agreement shall be binding upon their respective successors and assigns of the Parties. 
 Article 12:
Counterparts 
 This Agreement is written in Chinese. The original copy is prepared in quadruplicate, with one copy held by the Transferor and one by
the Transferee respectively, one copy retained by Sunshine Pharmaceutical and one copy submitted to the approval authorities, each of which shall be deemed original, and all of which shall constitute one and the same instrument. 
  

 5 

 IN WITNESS HEREOF, the Transferor and the Transferee have caused their respective authorized representatives to sign this
Agreement on the date and at the place first written above. 
 Transferor: Starry Investment Limited 
  

	
	For and on behalf of
	Starry Investment Limited
	
	 /s/:Liu Xin ( Authorized Representative)

	Authorized Signature(s)

 Transferee: Collected Mind Limited 
  

	
	For and on behalf of
	COLLECTED MIND LIMITED
	
	 /s/:Lou Dan ( Authorized Representative)

	Authorized Signature(s)

  

 6Share Transfer Agreement, dated as of July 18, 2006

 Exhibit 10.6 
 English translation of the executed copy 

 Agreement
Regarding Transfer of Equity Interest In 
 Shenyang Sunshine Pharmaceutical Co., Ltd. 
  

 By and Between 

Shenyang Keweier Hi-Tech Co., Ltd. 
 and 
 Collected Mind Limited 
  

 Equity Interest Transfer Agreement 
 This Agreement is entered into on 18 July 2006 in Shenyang by and between: 
 Transferor: Shenyang Keweier Hi-Tech Co., Ltd. 
 Legal Address: 2 Songhuahu Street, Shenyang Economic and Technological 
 Development Zone 
 Legal Representative: Xu Liping 
 And 
 Transferee: Collected Mind Limited 
 Legal Address: P.O. Box 957, Offshore Incorporations Centre, Road Town, Tortola, 
 British Virgin Islands 
 Authorized Representative: Lou Dan 
 WHEREAS: 
  

	1.	The Transferor is a limited liability company incorporated and validly existing pursuant to the laws of the People’s Republic of China (hereinafter referred to as
“China”), and legally holds a 50.88% equity interest (hereinafter referred to as the “Subject Equity Interest”) of Shenyang Sunshine Pharmaceutical Co., Ltd. (hereinafter referred to as “Sunshine Pharmaceutical”);

  

	2.	The Transferee is a company duly incorporated and validly existing pursuant to the laws of British Virgin Islands. It is validly qualified to be transferred of the equity interest
in Sunshine Pharmaceutical pursuant to relevant laws; 

  

	3.	Sunshine Pharmaceutical is a Sino-foreign equity joint venture duly incorporated in Shenyang and validly existing pursuant to the laws of China. Its principal business is to
research, develop, manufacture and sell biologically-engineered products and biochemical pharmaceuticals. It has a registered capital of Renminbi 62,974,046 which has already been fully contributed. Its existing shareholders are Chinese investors
the Transferor, China Traffic Supplies Northeast Co., Ltd. (hereinafter referred to as “Traffic Supplies”), Zhang Lisha as well as foreign investors Montgomery Biomedicine Lab Inc. of the USA (hereinafter referred to as
“Montgomery”), Lans Holdings Ltd. (hereinafter referred to as “Lans Holdings”) and Starry Investment Ltd. (hereinafter referred to as “Starry Investment”), among which the Transferor holds a 50.88% equity interest in
Sunshine Pharmaceutical; Traffic Supplies, 6.67%; Zhang Lisha, 8.23%; Montgomery, 17.89%; Lans Holdings 13.01% and Starry Investment, 3.33%. 

  

 1 

	4.	The Transferor desires to sell, and the Transferee desires to purchase, the Subject Equity Interest under the terms and conditions hereof. 

 NOW THEREFORE, the Transferor and the Transferee agree as follows: 
 Article
1: Equity Interest Transfer 
  

	1.	The Transferor hereby agrees to transfer the Subject Equity Interest to the Transferee pursuant to the stipulations hereof. 

  

	2.	The Transferee shall be transferred of the Subject Equity Interest pursuant to the stipulations hereof. 

  

	3.	As of the later of the date on which this Agreement becomes effective and the date on which Sunshine Pharmaceutical completes its registration with relevant government
administration offices industry and commerce for the transfer of the Subject Equity Interest, the Transferee shall immediately become the legal owner of the Subject Equity Interest and be entitled to and assume all the rights and obligations in
relation to the Subject Equity Interest. The Transferor shall no longer be entitled to any rights in relation to the Subject Equity Interest or assume any obligations or liabilities in relation to the Subject Equity Interest, unless otherwise
provided herein. The Transferor shall be obliged to assist the Transferee and Sunshine Pharmaceutical in completing all necessary legal procedures in relation to the transfer of the Subject Equity Interest. 

 Article 2: : Purchase Price and Payment 
  

	1.	As agreed by the Transferor and the Transferee upon negotiations, the consideration payable by the Transferee for the Subject Equity Interest shall be RMB 32,038,329;

  

	2.	It is agreed that the Transferee shall pay the transfer price in Hong Kong Dollar or US Dollar and pay 60% of the purchase price within six months from the date on which the
Transferee is registered as a shareholder of Sunshine Pharmaceutical with the industrial and commercial registration, and the remaining purchase price shall be paid in full within one year; 

  

 2 

	3.	Taxes payable in connection with this equity interest transfer shall be paid by both parties as required by relevant laws and regulations. 

 Article 3: Binding Effect 
 This Agreement shall be binding upon the
Parties at the time this Agreement is signed by the authorized representatives of both parties and approved by the competent foreign trade and economic cooperation authority. 
 Article 4: Representations and Warranties of Transferor 
 The Transferor hereby represents and warrants to the
Transferee that: 
  

	1.	The Transferor is a corporate legal person duly established and validly existing pursuant to the laws of China, and has the corporate power and authority to execute and perform this
Agreement; and this Agreement once executed is legal, valid and binding upon the Transferor. 

  

	2.	The Transferor is the owner of, and has legal and equitable title to the Subject Equity Interest, free and clear of any pledge or any other security interest or any claims by any
third party. The Transferor has the right to execute this Agreement and dispose of the entire Subject Equity Interest or any parts thereof. Such equity interest or any interest in relation thereto is not subject to any preferential right or other
similar rights. Upon completion of the equity interest transfer contemplated hereunder, the Transferee will be entitled to all the rights entitled to an owner of the Subject Equity Interest pursuant to laws, and may transfer or dispose of such
equity interest pursuant to laws, and such equity interest is free from any liens, charges claims, encumbrances, rights of others and restrictions on transfer under the incorporation documents of Sunshine Pharmaceutical or stipulations of the laws
of China. 

  

	3.	The execution, delivery and performance of this Agreement by the Transferor is neither in breach of any laws, administrative regulations, articles of association or other
organizational documents of the Transferor, nor in breach of any contracts, rules and regulations, court judgment or arbitration award which are binding upon the Transferor or its property. 

  

 3 

	4.	Sunshine Pharmaceutical has obtained all approvals, consents, authorizations and licenses necessary for its establishment and business operation. All such approvals, consents,
authorizations and licenses are valid and binding. To the knowledge of the Transferor, no event has ever occurred in connection with its business operation that affects the interest of the Transferee or is in breach of the laws and regulations of
China. 

  

	5.	No such fact that regarding Sunshine Pharmaceutical and that might change the original intent for the execution of this Agreement or any clauses hereof has not yet been disclosed.

  

	6.	Such representations, warranties and undertakings shall still remain in force and effect upon the completion of the transfer of the Subject Equity Interest to the Transferee,.

 Article 5: Representations and Warranties of Transferee 
 The Transferee hereby represents and warrants to the Transferor that: 
  

	1.	The Transferee is a limited company duly established and validly existing pursuant to the laws of British Virgin Islands, and possesses all the rights, authorities and capabilities
necessary for entering into and performing all the obligations and liabilities hereunder; and once executed the Agreement is legally and validly binding upon the Transferee. 

  

	2.	The execution, delivery and performance of this Agreement by the Transferee is neither in breach of any laws, administrative regulations, articles of association or other
organizational documents of the Transferee nor in breach of any contracts, rules and regulations, court judgment or arbitration award, which are binding upon the Transferee or its property. 

  

	3.	Such representations, warranties and undertakings shall still remain in force and effect after completion of the transfer of the Subject Equity. 

  

 4 

 Article 6: Confidentiality 
 Unless required by the relevant laws and regulations of China or relevant competent government departments, none of the parties may, prior to completion of the transaction contemplated herein, disclose any particular of this Agreement to
any third party that is not involved in such transaction without the consent of the other party. 
 Article 7: Matters not Covered by this Agreement

 The Transferor and the Transferee hereby agree that upon signing of this Agreement, they may further negotiate any matters that is not covered hereof and
may reach a supplemental agreement thereon. Such supplemental agreement shall constitute an inseparable integral part of this Agreement. 
 Article 8:
Liability for Breach of Contract 
 Either party is in breach of contract if it violates any of its representations, warranties or undertakings herein
or any clauses hereof. The default party shall indemnify the non-default party in whole and in full. 
 Article 9: Dispute Resolution 
 The parties to the Agreement shall resolve any disputes arising from the performance of this Agreement and in connection therewith through friendly negotiations, failing
which either party shall have the right to institute legal proceedings before a Chinese court with jurisdiction. 
 Article 10: Governing Law

 This Agreement is entered into under, and shall be governed, construed and controlled by the laws of China. 
 Article 11: Rights under the Agreement 
 None of the parties may
transfer its rights entitled hereunder without the written consent of the other party. This Agreement shall be binding upon their respective successors and assigns of the Parties. 
  

 5 

 Article 12: Counterparts 
 This Agreement is written in Chinese. The original copy is prepared in quadruplicate, with one copy held by the Transferor and one by the Transferee respectively, one copy retained by Sunshine Pharmaceutical and one copy submitted to the
approval authorities, each of which shall be deemed original, and all of which shall constitute one and the same instrument. 
 IN WITNESS HEREOF, the
Transferor and the Transferee have caused their respective authorized representatives to sign this Agreement as of the date and at the place first written above. 
  

	
	Transferor: Shenyang Keweier Hi-Tech Co., Ltd.
	/affixed with company seal of Shenyang Keweier Hi-Tech Co., Ltd./
	
	 /s/:Xu Liping( Authorized Representative)

	
	Transferee: Collected Mind Limited
	
	For and on behalf of
	COLLECTED MIND LIMITED
	
	 /s/:Lou Dan ( Authorized Representative)

	Authorized Signature(s)

  

 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}]]